Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Most Read

  1. Find out how pharma is fighting respiratory illnesses in the latest Pharma Technology Focus
  2. FDA accelerated review denial is a blow to Spectrum’s poziotinib
  3. Poxel closes enrolment in TIMES 2 trial of Imeglimin in Japan
  4. Cocrystal Pharma to study hepatitis C drug in Hong Kong
  5. Allergan assesses brazikumab in two clinical programmes for IBD

Latest Content

ARCA biopharma to study Gencaro in Phase III trial

ARCA biopharma has announced plans to investigate Gencaro (bucindolol hydrochloride) as a genetically-targeted therapy in a pivotal Phase III clinical trial for atrial fibrillation (AF) in patients with a certain type of heart failure (HF).

Intercept reports fibrosis improvement in NASH trial

Intercept Pharmaceuticals has reported positive top-line results from the pivotal Phase III REGENERATE clinical trial of obeticholic acid (OCA) in patients with liver fibrosis caused due to non-alcoholic steatohepatitis (NASH).

Latest News

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Go Top